Intellara Request access
Introducing Intellara

Know what your biotech competitors filed, registered and published this week.

Intellara tracks competitor clinical trials, papers, preprints and patents from official public sources, cross-checks every record against a second database, and cites the source on every line.

Request early access See a demo
ClinicalTrials.govTrials · NLM
PubMedPapers · NCBI
bioRxivPreprints
medRxivPreprints
Europe PMCCross-check · EMBL-EBI
CrossrefCross-check · DOIs
USPTOPatents

Official public sources only. European patents (EPO) are next.

What it does

The whole R&D race on one page.
No manual monitoring.

Company
watchlists

Follow a competitor across its trials, papers, preprints and patents. A person approves every name variant, and records that don't name the company are rejected. Here is how it went for Kite Pharma.

    Explore

    Cross-checked
    records

    Before a record reaches a report, it is checked against independent databases. Watch three real checks from our test run.

      Explore

      Change
      detection

      Every saved version of a record is kept. When a competitor's trial or patent changes, you see the old value, the new value and the date. These are two real changes the tool caught in Novartis patent applications on 12 Oct 2026.

      →
        Explore

        Kite Pharma · last 30 days

        data as of 12 Oct 2026
        Trials tracked59sponsor or collaborator
        Active trials30recruiting or ongoing
        Updated on registry8in last 30 days
        Papers125author affiliation
        2026-10-08 Phase 3KITE-753 vs. axicabtagene ciloleucel, relapsed/refractory LBCLRecruiting · lead sponsor NCT07479797
        2026-10-06 Phase 1Brexucabtagene autoleucel plus dasatinib in adult ALLActive, not recruiting NCT05993949
        2026-09-28 Phase 1KITE-363 in refractory autoimmune diseasesEnrolling by invitation NCT07038447
        2026-09-24 Phase 2Axi-cel plus glofitamab as second-line therapy for LBCLRecruiting NCT06213311

        Real output from a test run on 12 October 2026, built from public ClinicalTrials.gov, PubMed and USPTO records. Switch tabs and click any ID to open the source.

        Demo

        The newest biotech research,
        filtered to what you watch

        Pick an industry, a disease focus and the kind of result you care about: papers, preprints or patent applications. You get the newest matches from the last 90 days, each with its source ID and the companies behind it.

        Loading…

        Sources: Europe PMC (EMBL-EBI), which indexes PubMed and bioRxiv/medRxiv, and the USPTO Open Data Portal for patent applications. Company names are read from author affiliations, patent applicants and current owners.

        Verification

        Four checks behind
        every line of a report

        Every claim in a report must hold up when a reader clicks the citation.

        01

        The original record, kept

        The raw API response is stored for every version, so any number can be traced back and reprocessed.

        02

        A second database agrees

        Titles, DOIs and years are matched in Europe PMC and Crossref. Disagreements are flagged for review.

        03

        Retraction screen

        PubMed, Europe PMC and Crossref are all checked. In testing it caught a retracted 2021 glioblastoma case report.

        04

        Trial ↔ paper links, both ways

        A publication is linked to a trial only when the registry and PubMed point at each other.

        Sources

        One pipeline for trials,
        papers, preprints and patents

        No subscriptions to stitch together. Official APIs and openly licensed data only.

        CLINICALTRIALS.GOVtrials · daily PUBMEDpapers BIORXIV · MEDRXIVpreprints EUROPE PMCcross-check CROSSREFcross-check USPTOpatents · EPO next

        Every number links to its source

        Reports are plain data with a citation on every line. If a count is based on partial data, the report says so in the same place.

        PHASE1/PHASE2 · 8 trials · NCT01454596, NCT04077866, …
        Retraction · flagged by PubMed, Europe PMC, Crossref · PMID 33788825
        Trial ↔ paper · confirmed both ways · NCT05168423 ↔ PMID 42296961
        ⚠ Partial coverage · newest 300 of 5,098 matching trials stored
        Pricing

        Plans for labs, startups
        and investment teams

        Early-access pricing. Final pricing is set with our first customers.

        Academic
        Free or low cost

        Grad students, postdocs and tech transfer offices.

        • Topic watchlists
        • Cited landscape reports
        • Limited daily searches
        Join the waitlist
        Growth
        $250–$500 / month

        Early-stage biotech teams watching a crowded field.

        • Up to 3 company or pipeline watchlists
        • Paper, preprint and trial cross-referencing
        • Monthly change reports and company comparisons
        • Email alerts (in development)
        Request early access
        Enterprise
        $5k–$25k+ / year

        Pharma business development and life-science investors.

        • Unlimited watchlists and users
        • Custom data integrations
        • White-glove onboarding
        • API access, Slack alerts (planned)
        Talk to us
        Early access

        Get a free report on
        one competitor

        Email the company you watch most closely. We'll send back a cited activity report covering its trials, papers and preprints.